TNFRSF8 and Hodgkins lymphoma: NCT03602157 is a Phase I antiCD30 CAR-T cells co-expressing CCR4 for treatment of patients with Hodgkin ́s lymphoma and CD30+ cutaneous T-cell lymphoma (CTCL).